MDACC Study No:2011-0382 ( NCT No: NCT01363817)
Title:Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Principal Investigator:Patrick Zweidler-McKay
Treatment Agent:BMS-906024
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of BMS-906024 that can be given to patients with relapsed or refractory T cell
leukemia or lymphoma. The safety of this drug will also be studied.

BMS-906024 is designed to block an enzyme called gamma secretase. This enzyme
is important in most T cell leukemias and lymphomas. Blocking this enzyme may
help to control the disease. This is the first study using BMS-906024 in

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I
Treatment Agents:BMS-906024
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Patrick Zweidler-McKay
For Clinical Trial Enrollment:713-745-4616
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults